Skip to content
Screener

Roivant Sciences ROIV Return on invested capital

Return on invested capital at other companies

Amgen logo
AmgenAMGN
14.8%+3.6pp
Moderna logo
ModernaMRNA
-43.8%+18.5pp
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
16.7%+8.4pp
AbbVie logo
AbbVieABBV
17.1%—
Regenxbio logo
RegenxbioRGNX
-103.9%+612pp
Revvity logo
RevvityRVTY
3.6%+0.5pp

Other financials

Income statement

See full
Revenue$1.4M-33.5%
Operating income-$366.0M-28.5%
Net income-$189.8M+15.0%
EPS (diluted)-$0.26+21.2%

Balance sheet

See full
Cash & equivalents$77.1M-18.7%
Total debt$107.2M+7.5%
Total equity$4.2B-2.6%
Total assets$5.3B+5.4%

Cash flow

See full
Operating cash flow-$270.5M-32.4%
CapEx$419.0K-89.6%
Free cash flow-$270.9M-30.0%

Valuation

See full
Market cap$25B+214%
Enterprise value$25.03B+215%
P/S3,318.5×+2,976×

Profitability

See full
Operating margin-9,130.5%-13,995pp
Net margin-6,079.9%-6,193pp
FCF margin-10,901%-22,382pp

Returns & leverage

See full
Return on equity-17.1%-17.7pp
Debt / equity0×0.0×
Current ratio16.7×-23.8×

Where this comes from

Calculated from Roivant Sciences’s reported figures.

nopat/invested capital=-25.6%

Based on trailing twelve months.

The source filing: Roivant Sciences’s 10-Q, filed February 6, 2026. Open the filing →

Filed
Feb 6, 2026, 7:31 AM EST
Fiscal quarter
Q3 FY2025
Calendar quarter
Q4 2025
Accession
0001635088-26-000011

FAQ

What is Roivant Sciences's return on invested capital?
Roivant Sciences (ROIV) reported return on invested capital of -25.6% in Q4 2025.
What does return on invested capital mean?
Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.

Ask your AI about Roivant Sciences's return on invested capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude